nuclear receptor binding protein 2Genealiases: TRG16 · pp9320
Q-omics provides the consensus-scored NRBP2 profile across patient tissues and cancer cell-line models. NRBP2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NRBP2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, NRBP2 protein abundance shows 20,432 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where NRBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRBP2 survival associations across molecular data types. NRBP2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRBP2 RNA expression–survival associations across cancer types. High NRBP2 expression shows unfavorable associations in KIRC, BLCA, ACC, LAML and PRAD, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NRBP2 RNA expression.
This table summarizes NRBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NRBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRBP2 shows lower tumor expression in BRCA and higher tumor expression in HNSC, KIRC, KIRP, COAD and LIHC. The HNSC box plot shows higher NRBP2 RNA expression in tumor versus normal tissue (log2 FC = +1.626, t-test p < 0.001).
This table shows molecular features associated with NRBP2 in patient tissues and cancer cell lines. In patient samples, NRBP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NRBP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
